{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:34:28Z","timestamp":1792722868639,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaad.2025.11.033","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:17:30Z","timestamp":1763630250000},"page":"802-809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy S.","family":"Eakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"McCormick Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Langan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.M.","family":"van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Eng","family":"Choon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Ramessur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.11.033_bib1","series-title":"WHO Consolidated Guidelines on Tuberculosis: Module 1: Prevention \u2013 Tuberculosis Preventive Treatment","year":"2024"},{"key":"10.1016\/j.jaad.2025.11.033_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/745483","article-title":"Role of TNF-alpha, IFN-gamma, and IL-10 in the development of pulmonary tuberculosis","volume":"2012","author":"Cavalcanti","year":"2012","journal-title":"Pulm Med"},{"key":"10.1016\/j.jaad.2025.11.033_bib3","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2025.11.033_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-alpha antagonists: a systematic review and meta- analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaad.2025.11.033_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2025.11.033_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jaad.2025.11.033_bib7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1172\/JCI39143","article-title":"Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed","volume":"119","author":"Miller","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2025.11.033_bib8","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.4049\/jimmunol.0903332","article-title":"Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung","volume":"184","author":"Yoshida","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2025.11.033_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cytogfr.2010.10.004","article-title":"IL-17 and Th17 cells in tuberculosis","volume":"21","author":"Torrado","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jaad.2025.11.033_bib10","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1084\/jem.20100265","article-title":"Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis","volume":"207","author":"Cruz","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2025.11.033_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jdv.20287","article-title":"Treatment of psoriasis with biologic and non-biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: recommendations from a SPIN-FRT expert consensus","volume":"39","author":"Torres","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.11.033_bib13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2025.11.033_bib14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","article-title":"IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available","volume":"175","author":"Khader","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2025.11.033_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.smim.2007.10.009","article-title":"Th17 cells and mucosal host defense","volume":"19","author":"Aujla","year":"2007","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaad.2025.11.033_bib16","first-page":"165","article-title":"Innate type 1 immune response, but not IL-17 cells control tuberculosis infection","volume":"44","author":"Segueni","year":"2021","journal-title":"Biom J"},{"key":"10.1016\/j.jaad.2025.11.033_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/srep36923","article-title":"Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNF alpha neutralization","volume":"6","author":"Segueni","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaad.2025.11.033_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008312","article-title":"TNF-alpha antagonists differentially induce TGF-beta1-dependent resuscitation of dormant-like Mycobacterium tuberculosis","volume":"16","author":"Arbues","year":"2020","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jaad.2025.11.033_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2017.34","article-title":"Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections","volume":"6","author":"Kammuller","year":"2017","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jaad.2025.11.033_bib20","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.11.033_bib21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jdv.16866","article-title":"Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis-time for a paradigm change","volume":"35","author":"Nogueira","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.11.033_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib23","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to- severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2025.11.033_bib24","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2025.11.033_bib25","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1093\/rheumatology\/keab566","article-title":"Corrigendum to: safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"60","author":"Genovese","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2025.11.033_bib26","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.jaad.2020.06.012","article-title":"No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: a report from 16 clinical studies of patients with psoriasis or psoriatic arthritis","volume":"83","author":"Mrowietz","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2025.11.033_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2025.11.033_bib29","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.42282","article-title":"Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase IIb randomized controlled trial and its open-label extension study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib30","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.42280","article-title":"Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a phase IIb randomized controlled trial and its open- label extension study","volume":"74","author":"Coates","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.033_bib31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjd.17604","article-title":"Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis","volume":"181","author":"Romiti","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib32","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v105.42081","article-title":"Safety of interleukin inhibitors in psoriatic patients with latent tuberculosis infection without chemoprophylaxis: a systematic review","volume":"105","author":"Li","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2025.11.033_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5302","article-title":"Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: a multi-case report analysis","volume":"10","author":"Fiorella","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaad.2025.11.033_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","article-title":"In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis","volume":"20","author":"Galluzzo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaad.2025.11.033_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09546634.2018.1543843","article-title":"Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies","volume":"29","author":"Lasagni","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2025.11.033_bib36","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s10067-023-06630-8","article-title":"Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection","volume":"42","author":"Liu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1684\/ejd.2020.3909","article-title":"Safety of secukinumab in psoriasis patients with latent tuberculosis infection","volume":"30","author":"Machado","year":"2020","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib38","first-page":"e26","article-title":"No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: multicenter case series of 35 patients","volume":"38","author":"Manzanares","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.11.033_bib39","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1982","article-title":"Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in Northern Italy","volume":"102","author":"Mastorino","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2025.11.033_bib40","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1080\/09546634.2022.2062280","article-title":"Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection","volume":"33","author":"Megna","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2025.11.033_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000501989","article-title":"Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis","volume":"11","author":"Ribero","year":"2019","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14512","article-title":"Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study","volume":"33","author":"Shu","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2025.11.033_bib43","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s13555-023-00998-w","article-title":"A propensity score- matched study on the changes of TB status and TB-IGRA values in patients with psoriasis with latent TB receiving secukinumab","volume":"13","author":"Xiao","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.11.033_bib44","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s13555-024-01130-2","article-title":"Interleukin-17A inhibitors in patients with psoriasis and tuberculosis infection: a 2-year prospective study on safety without preventive treatment","volume":"14","author":"He","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2025.11.033_bib45","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41598-017-06899-1","article-title":"Active tuberculosis incidence and characteristics in patients treated with tumor necrosis factor antagonists according to latent tuberculosis infection","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaad.2025.11.033_bib46","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2025.11.033_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/cmi.2017.128","article-title":"The crucial roles of Th17-related cytokines\/signal pathways in M. tuberculosis infection","volume":"15","author":"Shen","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaad.2025.11.033_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq5204","article-title":"Human IL-23 is essential for IFN-\u03b3-dependent immunity to mycobacteria","volume":"8","author":"Philippot","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaad.2025.11.033_bib49","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaad.2025.11.033_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaad.2025.11.033_bib51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","article-title":"Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis","volume":"47","author":"Strober","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2025.11.033_bib52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.16724","article-title":"Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib53","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib55","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2025.11.033_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"39","author":"Gao","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib57","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2025.11.033_bib58","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: results from the phase 2 open-label extension study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2025.11.033_bib59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib60","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1111\/jdv.16460","article-title":"Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials","volume":"34","author":"Puig","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.11.033_bib61","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/ced.14199","article-title":"Successful use of guselkumab in the treatment of severe hidradenitis suppurativa","volume":"45","author":"Kearney","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2025.11.033_bib62","first-page":"228","article-title":"Novel therapeutic approaches to psoriasis and risk of infectious disease","volume":"10","author":"Motolese","year":"2022","journal-title":"Biomedicine"},{"key":"10.1016\/j.jaad.2025.11.033_bib63","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral interleukin-23-receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225032323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:21:55Z","timestamp":1777018915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225032323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0190962225032323"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.033","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}